Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Applied Digital | GE Vernova | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | none The FY2026 10-K (filed 2026-07-29) shows contracted revenue, not a demonstrated competitive edge. About 1,410 MW is leased under 15-year take-or-pay, non-cancellable base terms worth about $36.2 billion, but only about 100 MW of the roughly 1.5 GW that is contracted and either operating or under construction was operating and earning revenue at May 31, 2026, and Item 1A says "lessees may have the right to terminate applicable leases if there are significant delays in construction." Item 1A also concedes "We do not have the resources to compete with larger providers of similar products or services at this time," and the Competition section names 13 power-advantaged developers the company competes with. Signed leases give revenue visibility, but the filing does not show a durable advantage. | wide FY2025 10-K (filed 2026-01-29): the installed base generates approximately 25% of the world's electricity; the Power segment carries ~$94.4B of remaining performance obligations with ~1,800 of ~7,000 installed gas turbines under long-term service agreements averaging ~10 years of remaining contract life; and the filing states demand is 'exceeding available capacity' for its products — a contracted, decade-scale service annuity on proprietary installed equipment. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | none The 10-K claims three advantages: power-advantaged sites (it believes securing power and interconnection ahead of demand is 'the principal constraint on new HPC capacity and a core differentiator for us from many of our competitors'), a standardized 'franchise-style' design, and hyperscaler master service and master telecom service agreements 'that are difficult to obtain.' The filing does not show any of them to be durable. Its Competition section says competition 'centers on securing and developing sites with access to large-scale, reliable, and cost-competitive power and interconnection' and names 13 power-advantaged developers going after the same leases, and Item 1A concedes it lacks the resources to compete with larger providers. Signed leases are take-or-pay and non-cancellable, so a tenant leaving for convenience owes 'the full remaining contractual value,' but that is contractual lock-in on each lease rather than a moat source, so no moat type is assigned. | switching costs 10-K: ~1,800 gas turbines under long-term service agreements with ~10-year average remaining life, plus services agreements on ~24,000 of ~59,000 installed onshore wind turbines — service revenue is contractually tied to GE Vernova's own installed fleet; the filing adds it derives 'a sustained competitive advantage both from our IP portfolio as well as technical know-how embedded in our products and manufacturing techniques developed over decades'. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | behind The 10-K makes no leadership claim and gives no ranking or share figure. Item 1A concedes "We do not have the resources to compete with larger providers of similar products or services at this time" and that some rivals have "substantially greater liquidity and financial resources than we do." Its Competition section places APLD against established operators (Digital Realty, Equinix), hyperscalers that build their own capacity, independent developers and 13 named power-advantaged developers (IREN, Cipher Digital, TeraWulf, Hut 8, Riot, CleanSpark, HIVE, Core Scientific, Bitdeer, Galaxy Digital, Fermi, Keel Infrastructure, MARA). | co leader 10-K opens with 'GE Vernova is a global leader in the electric power industry' and its installed base generates ~25% of world electricity, but the filing names peer-scale competitors in every segment — Siemens Energy in both Power and Electrification, Mitsubishi Power, Vestas, Hitachi Energy, Schneider Electric, ABB — so co-leader across the portfolio rather than clear leader. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak Item 1A says "Due to the limited number of hyperscalers, we expect that a limited number of customers will continue to account for a high percentage of our revenue for the foreseeable future," and that if customers' equipment usage declines or they discontinue use of its facilities, APLD "may be compelled to lower our lease prices in some instances or risk losing a significant customer." One customer was 59% of FY2026 revenue from continuing operations. Take-or-pay, non-cancellable terms protect contracted revenue over the base term, and Note 19 reports a $39.1M HPC Hosting segment profit on $385.3M of segment revenue in FY2026, but those terms are agreed with a small group of concentrated buyers. | strong 10-K: 'increasing demand exceeding available capacity', Electrification customer lead-times 'increased as a result of demand outstripping supply', and both Power and Electrification state they adjust pricing 'in line with market demand, inflation, and industry dynamics'; trade press (Power Engineering, 2026-04-23) reported new gas-turbine order pricing in H1 2026 tracking 10-20 points higher on a dollar-per-kilowatt basis than Q4 2025 orders. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Applied Digital designs, builds and operates purpose-built, liquid-cooled HPC data centers, which it calls 'AI factories', and leases the capacity to CoreWeave and investment-grade hyperscalers. At May 31, 2026 its 10-K lists five campuses (Polaris Forge 1-3 and Delta Forge 1-2) with about 1,410 MW contracted under roughly 15-year take-or-pay, non-cancellable leases worth about $36.2 billion over the base terms. The filing claims three sources of advantage: it controls power-advantaged sites, it uses a standardized 'franchise-style' design built to deliver about 150 MW in about 14 to 18 months, and it holds hyperscaler master agreements that are 'difficult to obtain.' The same document shows how early the company is. About 100 MW was operating and earning revenue. One customer was 59% of FY2026 revenue from continuing operations. It competes with Digital Realty, Equinix, hyperscalers that build their own capacity and 13 named power-advantaged developers, and it concedes that it lacks the resources to compete with larger providers. Signed leases give long-dated revenue visibility, but the filing does not show a durable competitive advantage. | GE Vernova's moat rests on its installed base: the FY2025 10-K states its equipment generates approximately 25% of the world's electricity, with ~7,000 installed gas turbines (~1,800 under long-term service agreements averaging ~10 years of remaining life) and ~$94.4B of Power-segment remaining performance obligations. The filing reports demand 'exceeding available capacity', lengthening Electrification lead-times 'as a result of demand outstripping supply', and pricing adjusted with demand — scarcity trade press later quantified as new gas-turbine order pricing tracking 10-20 points higher per kW in H1 2026 than Q4 2025, with only ~10 GW of production slots left across 2029-2030 (Power Engineering, 2026-04-23). The moat is not uniform: the 10-K risk section flags intensifying competition as manufacturers from China 'improve quality and reliability and pursue markets outside their home countries', and Offshore Wind is delivering its backlog under project-cost and execution pressure, compounded by the U.S. Interior Department's December 22, 2025 pause of leases for all large-scale U.S. offshore projects under construction, which directly impacted the Vineyard Wind timeline. Nuclear adds optionality: the 10-K cites an SMR deployment agreement it calls 'the first commercial contract of its kind in North America' via its joint ventures with Hitachi. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Developer and landlord of power-advantaged, liquid-cooled AI data-center capacity, leased long-term to CoreWeave and investment-grade hyperscalers. | Power supplier to the AI buildout: the 10-K states gas power serves 'rising electricity demand from hyperscalers and data centers' and Electrification benefits from orders to electrify data centers 'playing a key role in the development of artificial intelligence (AI)'; trade press (Power Engineering, 2026-04-23) put roughly 20% of the ~100 GW of gas capacity under contract as explicitly tied to data-center load. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.35 at weight 0.20 · swarm bullish Editorial prior, not backtested. |